Skip to main content
David Spriggs, MD, Oncology, Boston, MA, Massachusetts General Hospital

DavidRSpriggsMDFASCO

Oncology • Boston, MA

Gynecologic Cancer, Hematologic Oncology

Professor in Residence

Join to view full profile

Dr. Spriggs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Spriggs' full profile

Already have an account?

Summary

  • Consultant in early stage clinical development in immuno-oncology.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1985
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1979 - 1982
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
  • University of Wisconsin School of Medicine & Public Health
    University of Wisconsin School of Medicine & Public HealthClass of 1977

Certifications & Licensure

  • Massachusetts
    Massachusetts, MA 1982 - 2024
  • NY State Medical License
    NY State Medical License 1978 - 2022
  • ME State Medical License
    ME State Medical License 2020 - 2021
  • WI State Medical License
    WI State Medical License 1989 - 1993
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow, American Society of Clinical Oncology American Society of Clinical Oncology, 2016
  • America's Top Doctors Castle Connolly, 2005-2016
  • Fellow, American College of Physicians American college of physicians, 2014
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer  
    David Spriggs, MD, Clinical Cancer Research

Press Mentions

  • ASCO Reading Room | Working PARP Inhibitors Harder in Ovarian Ca
    ASCO Reading Room | Working PARP Inhibitors Harder in Ovarian CaApril 2nd, 2019
  • Massachusetts Medical Society Announces Members of Search Committee for New England Journal of Medicine Editor-in-Chief
    Massachusetts Medical Society Announces Members of Search Committee for New England Journal of Medicine Editor-in-ChiefNovember 2nd, 2018
  • Shop Talk
    Shop TalkJune 25th, 2017
  • Join now to see all

Grant Support

  • Early Clinical Trials Of New Anti-Cancer Agents With Phase 1 EmphasisNational Cancer Institute2009–2012
  • Career Development ProgramNational Cancer Institute2010–2011
  • Clinical Investigator Development In Solid Tumor OncologyNational Cancer Institute2006–2010
  • Novel Strategy For The Re-Induction &Consolidation Of Remission In Ovary CancerNational Cancer Institute2007–2009
  • Epithelial Ovarian Cancer Program ProjectNational Cancer Institute2001–2009
  • Novel Strategy For Clinical Remission In Ovarian CancerNational Cancer Institute2005–2006
  • Cancer Chemotherapy Program ProjectNational Cancer Institute2005
  • Phase I Clinical Trials Of Novel AgentsNational Cancer Institute2003–2005
  • Nf-Kb Mediated Drug Resistance In Ovarian CancerNational Cancer Institute2000–2004
  • New Investigator Training In Drug DevelopmentNational Cancer Institute2000–2004
  • Core--PharmacologyNational Cancer Institute2001–2002
  • Core--BiostatisticsNational Cancer Institute2001–2002
  • Phase I Studies Of Anticancer AgentsNational Cancer Institute1998–2002
  • Developmental ChemotherapyNational Cancer Institute1996–2002
  • Ovarian Cancer--Clinical TrialsNational Cancer Institute1996–1997
  • Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–1997
  • TNF Gene Regulation In Breast And Ovary CancerNational Cancer Institute1994–1997
  • Molecular Mechanisms Of Tumor Necrosis FactorNational Cancer Institute1990–1991
  • Molecular Mechanisms Of Tumor Necrosis Factor 1r01ca4772National Cancer Institute1989
  • Molecular Mechanisms Of Tumor Necrosis FactorNational Cancer Institute1989
  • Pharmacodynamics Of ARA-C Therapy In Human MalignancyNational Cancer Institute1988–1989
  • The Pharmacodynamics Of ARA-C In Human MalignancyNational Cancer Institute1985–1987

Hospital Affiliations

Dr. David Spriggs, Dr. David Spriggs, MD, Dr. D Spriggs, Dr. David R Spriggs